Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Killock

Showing results (1-10 of 304) with videos related to

Pageof 31
Sort By:
Nature Reviews. Clinical Oncology|December 19, 2018
New high-risk molecular subtypes of DLBCL identifiedDavid Killock
Nature Reviews. Clinical Oncology|November 12, 2024
First-line triplet therapy for advanced-stage PIK3CA-mutant HR<sup>+</sup> breast cancer improves outcomesDavid Killock
Nature Reviews. Clinical Oncology|May 8, 2020
REACH2: ruxolitinib for refractory aGvHDDavid Killock
Nature Reviews. Clinical Oncology|May 3, 2020
Anti-CD22 CAR T cells in ALLDavid Killock
Nature Reviews. Clinical Oncology|December 23, 2021
Pembrolizumab for HER2<sup>+</sup> gastric cancerDavid Killock
Nature Reviews. Clinical Oncology|September 29, 2022
New PEARLS of adjuvant wisdomDavid Killock
Nature Reviews. Clinical Oncology|September 23, 2015
Haematological cancer: Repositioned to attack CML cellsDavid Killock
Nature Reviews. Clinical Oncology|March 23, 2016
Haematological cancer: PomCyDex - a lower-cost option in refractory myeloma?David Killock
Nature Reviews. Clinical Oncology|March 2, 2016
Gastrointestinal cancer: PICCOLO--changing the tune of anti-EGFR therapyDavid Killock
Nature Reviews. Clinical Oncology|April 29, 2018
Nivolumab-ipilimumab - exploiting the mutation burden of NSCLCsDavid Killock
Pageof 31

Showing results (1-10 of 304) with videos related to

Sort By:
Pageof 31
Nature Reviews. Clinical Oncology|December 19, 2018
New high-risk molecular subtypes of DLBCL identifiedDavid Killock
Nature Reviews. Clinical Oncology|November 12, 2024
First-line triplet therapy for advanced-stage PIK3CA-mutant HR<sup>+</sup> breast cancer improves outcomesDavid Killock
Nature Reviews. Clinical Oncology|May 8, 2020
REACH2: ruxolitinib for refractory aGvHDDavid Killock
Nature Reviews. Clinical Oncology|May 3, 2020
Anti-CD22 CAR T cells in ALLDavid Killock
Nature Reviews. Clinical Oncology|December 23, 2021
Pembrolizumab for HER2<sup>+</sup> gastric cancerDavid Killock
Nature Reviews. Clinical Oncology|September 29, 2022
New PEARLS of adjuvant wisdomDavid Killock
Nature Reviews. Clinical Oncology|September 23, 2015
Haematological cancer: Repositioned to attack CML cellsDavid Killock
Nature Reviews. Clinical Oncology|March 23, 2016
Haematological cancer: PomCyDex - a lower-cost option in refractory myeloma?David Killock
Nature Reviews. Clinical Oncology|March 2, 2016
Gastrointestinal cancer: PICCOLO--changing the tune of anti-EGFR therapyDavid Killock
Nature Reviews. Clinical Oncology|April 29, 2018
Nivolumab-ipilimumab - exploiting the mutation burden of NSCLCsDavid Killock
Pageof 31